LON:DXRX Diaceutics (DXRX) Share Price, News & Analysis GBX 116.50 0.00 (0.00%) As of 07/4/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Diaceutics Stock (LON:DXRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Diaceutics alerts:Sign Up Key Stats Today's Range 114.30▼ 11750-Day Range 112.50▼ 14052-Week Range 106▼ 151Volume282,688 shsAverage Volume126,020 shsMarket Capitalization£98.32 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 160Consensus RatingBuy Company Overview At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®. Read More Receive DXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DXRX Stock News HeadlinesDiaceutics Enhances Employee Incentives with Share PurchasesJune 6, 2025 | tipranks.comDiaceutics PLC Announces AGM and Annual Report ReleaseMay 21, 2025 | tipranks.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. July 6 at 2:00 AM | Porter & Company (Ad)Diaceutics PLC Expands Employee Share Incentive PlanApril 29, 2025 | tipranks.comDiaceutics PLC Enhances Employee Shareholding with New Share Incentive PlanApril 3, 2025 | tipranks.comDiaceutics PLC Aligns Employee Incentives with Share AwardsMarch 3, 2025 | tipranks.comDiaceutics Director Increases Stake Signaling Confidence in Company GrowthJanuary 31, 2025 | tipranks.comDiaceutics Enhances Employee Incentive Program with Share AwardsJanuary 30, 2025 | tipranks.comSee More Headlines DXRX Stock Analysis - Frequently Asked Questions How have DXRX shares performed this year? Diaceutics' stock was trading at GBX 123 at the beginning of 2025. Since then, DXRX stock has decreased by 5.3% and is now trading at GBX 116.50. How were Diaceutics' earnings last quarter? Diaceutics PLC (LON:DXRX) issued its earnings results on Tuesday, May, 13th. The company reported ($2.02) earnings per share (EPS) for the quarter. Diaceutics had a negative trailing twelve-month return on equity of 7.15% and a negative net margin of 10.90%. How do I buy shares of Diaceutics? Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Diaceutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Diaceutics investors own include 4D pharma (DDDD), Rolls-Royce Holdings plc (RR.L), Abcam (ABC), B&M European Value Retail (BME), BP (BP), Coats Group (COA) and genedrive (GDR). Company Calendar Last Earnings5/13/2025Today7/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolLON:DXRX CIKN/A Webwww.diaceutics.com PhoneN/AFaxN/AEmployees151Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 160 High Stock Price TargetGBX 160 Low Stock Price TargetGBX 160 Potential Upside/Downside+37.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)GBX (3.37) Trailing P/E RatioN/A Forward P/E Ratio115.26 P/E GrowthN/ANet Income-£2.84 million Net Margins-10.90% Pretax MarginN/A Return on Equity-7.15% Return on Assets-6.06% Debt Debt-to-Equity Ratio0.39 Current Ratio4.85 Quick Ratio9.92 Sales & Book Value Annual Sales£26.08 million Price / Sales3.77 Cash FlowGBX 37.34 per share Price / Cash Flow3.12 Book ValueGBX 45.87 per share Price / Book2.54Miscellaneous Outstanding Shares84,393,829Free FloatN/AMarket Cap£98.32 million OptionableNot Optionable Beta0.58 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (LON:DXRX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diaceutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Diaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.